APA (7th ed.) Citation

SS, B., G, A., AM, B., ML, B., K, B., C, d. L. C., . . . D, S. (2026). Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia. European journal of endocrinology, 195(1), 10. https://doi.org/10.1093/ejendo/lvag099

Chicago Style (17th ed.) Citation

SS, Beck-Nielsen, et al. "Second Interim Analysis of the Post-authorisation Safety Study (PASS) of Burosumab in Paediatric Patients with X-linked Hypophosphataemia." European Journal of Endocrinology 195, no. 1 (2026): 10. https://doi.org/10.1093/ejendo/lvag099.

MLA (9th ed.) Citation

SS, Beck-Nielsen, et al. "Second Interim Analysis of the Post-authorisation Safety Study (PASS) of Burosumab in Paediatric Patients with X-linked Hypophosphataemia." European Journal of Endocrinology, vol. 195, no. 1, 2026, p. 10, https://doi.org/10.1093/ejendo/lvag099.